Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "GTBL"

2 News Found

Gujarat Themis Biosyn to acquire anti-TB and anti-infective brands from Sanofi for EUR 158 Million
News | April 24, 2026

Gujarat Themis Biosyn to acquire anti-TB and anti-infective brands from Sanofi for EUR 158 Million

Deal includes 13 branded generic products across 55+ countries; acquisition expected to strengthen global anti-infective portfolio and expand regulated market presence

Amalgamation of Gujarat Themis Biosyn with Themis Medicare
News | November 23, 2024

Amalgamation of Gujarat Themis Biosyn with Themis Medicare

The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL

Latest Stories

Takara Bio, Resistomap join forces to streamline AMR surveillance from environmental samples

New genomics clinic by Fortis Hospitals targets early disease detection

Rossari Biotech reviews capex, delays Unitop and Tristar expansion rollout

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Local manufacturing, deeper CDMO ties, region-specific solutions remain our top priorities in next 3–5 years: Ganesh Bade, Director Bioprocessing–IMEA, Avantor
Ganesh Bade Director Bioprocessing–IMEA, Avantor
We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET
We believe in trust-driven clinical conversations to cut through medical misinformation: Saurav Kasera, Founder, CLIRNET
Saurav Kasera Founder, CLIRNET
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group
Only 4-5 Indian pharma companies have a strong presence in Russia, opportunity is far bigger now: Manish Kumar, Vice-Chairman, Moscow Chamber of Commerce, Indian Commission; and President, Soltex Group

Packaging